NCT04068207CompletedPhase 2
Minocycline Treatment in Retinitis Pigmentosa
The Efficacy and Safety of Oral Minocycline in the Treatment of Retinitis Pigmentosa: An Open-label Clinical Trial
Source: ClinicalTrials.gov · Last updated 27 Dec 2023
Brief summary (registry, in English)
The aim of this study is to evaluate the efficacy and safety of oral minocycline (100mg/d), administered for 6 months, for the treatment of patients with retinitis pigments(RP).
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (actual)
- First submitted
- 23 Aug 2019
- Start date
- 25 Aug 2019
- Primary completion date
- 31 Jan 2023
- Lead sponsor
- Sun Yat-sen University
- Diseases
- Retinitis pigmentosa
- NCT number
- NCT04068207
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 35
- From 25 Aug 2019 to the primary completion date, 31 Jan 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Vitamin A, DHA and other neurotrophic drugs were used within 3 months.
Other illness
- Other ocular diseases or fundus diseases except cataract: glaucoma, diabetic retinopathy, retinal detachment.
- Tetracycline or minocycline allergy or intolerance.
- Renal or hepatic insufficiency.
- History of thyroid neoplasm.
- History of idiopathic intracranial hypertension.
Other
- Glucocortticoids or tetracycline were used within 3 months.
- Pregnant or lactating females.
Who the study is looking for
- Clinical diagnosis of Retinitis Pigmentosa: nyctalopia, visual field constriction and loss of central vision; degeneration of peripheral rod photoreceptor and retinal pigment epithelium cells.
- Age from 18 to 60 years old.
- BCVA \>20/100(0.2) at least in one eye.
- Full-field cone electroretinogram amplitude to 30-Hz flashes \>0uV at least in one eye.
- Written informed consent is provided.
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhongshan Ophthalmic Center,Sun Yat-Sen University Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.